Astellas Pharma Inc (4503.T) stock: key figures, P/E, revenue and dividend
Health Care · Japan · ISIN JP3942400007
Astellas Pharma Inc financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 1.91 tn JPY | 2.14 tn JPY |
| Gross profit | 1.56 tn JPY | 1.59 tn JPY |
| EBIT | 263.54 bn JPY | 419.70 bn JPY |
| Net income | 50.75 bn JPY | 291.54 bn JPY |
| Diluted EPS – continuing operations | 28.23 JPY | 162.31 JPY |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Astellas Pharma Inc
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
More stocks
- AXIA Energia SA (AXICY)
- Hapag-Lloyd (HLAG.DE)
- SMC Corp (6273.T)
- FIRST CITIZENS BANCSHARES INC /DE/ (FCNCA)
- Coupang, Inc. (CPNG)
- NARI Technology Co Ltd (600406.SS)
- H & M Hennes & Mauritz AB (HM B.ST)
- Aviva PLC (AV.L)
- DTE Energy (DTE)
- SharkNinja, Inc. (SN)
- Canon Inc (7751.T)
- Ryanair Holdings PLC (RYA.IR)
Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.